Safety & Regulation News
Every article we’ve published on Safety & Regulation, newest first — 16 in total. Each one is sourced to primary regulatory, trial, or peer-reviewed documents and links back to the original.
Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance
The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.
Cagrilintide Bone Density Trial Opens With Semaglutide Comparator
A newly posted cagrilintide bone density trial puts an amylin analogue head-to-head with semaglutide and with the CagriSema combination, and its stated purpose is bone health rather than weight. For anyone tracking a GLP-1 or incretin protocol, it is a signal that skeletal outcomes are moving from footnote to primary question.
Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins
A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.
Semaglutide Lifespan Mice Study: What the Nature Paper Actually Found
A semaglutide lifespan mice study published in Nature reports that older female mice given the GLP-1 drug lived longer and scored better on health measures than untreated animals. The National Institutes of Health says the effect went beyond what calorie restriction alone produced — a claim that will shape how the drug class is discussed for years, and one that arrives the same week European regulators fined news outlets for over-enthusiastic GLP-1 coverage.
FDA Unapproved GLP-1 Drugs Alert: What the Agency Is Warning About
The FDA refreshed its standing alert on unapproved GLP-1 drugs used for weight loss on September 1, 2026, restating why products sourced outside the approved supply chain carry risks the agency cannot vouch for. For anyone tracking a semaglutide or tirzepatide protocol, the practical question is where the product came from and what is actually on the label.
Retatrutide Diabetic Ketoacidosis Case Report Involves Online Source
A single-patient report newly indexed in PubMed describes retatrutide diabetic ketoacidosis risk in a type 1 diabetes patient who bought the investigational drug online while also fighting a bacterial gut infection. It is the kind of case that surfaces when an unapproved molecule circulates faster than its clinical evidence.
Semaglutide heart effects: new cardiac CT and tissue studies
A cluster of new peer-reviewed publications shifts attention from weight and glucose toward semaglutide heart effects — specifically cardiac structure, gene expression in human heart tissue, and cardiovascular outcomes in people with diabetes and existing vascular or kidney disease. None of them changes how anyone takes the drug, but together they show where the research is heading.
Synthetic Semaglutide Claims Challenged Over Reporting Gaps
A newly indexed letter in Diabetes, Obesity & Metabolism takes aim at the evidence behind synthetic semaglutide used for weight management, arguing that reporting gaps make the clinical claims hard to evaluate. For anyone tracking a compounded or non-brand GLP-1 protocol, the argument is about what you can and cannot infer from a study that says the molecule is the same.
Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment
The registry entry for TRIUMPH-Outcomes, the phase 3 retatrutide cardiovascular outcomes trial, was updated on August 24 to show the study active and closed to new participants. It is the largest single trial in Eli Lilly's retatrutide program and the one that will decide whether the triple agonist can claim organ-protection benefits rather than weight loss alone.
Semaglutide cognitive side effects: 13,007-patient BMJ study
Three peer-reviewed papers examining semaglutide cognitive side effects and broader neuropsychiatric signals from GLP-1 receptor agonists were indexed within days of each other. The largest is a retrospective cohort of 13,007 people in the United States who already carried a psychiatric diagnosis.
Retatrutide Phase 3 Trial Completed in 2,335-Person Obesity Study
A ClinicalTrials.gov record updated August 21, 2026 shows Eli Lilly's largest registered retatrutide phase 3 trial completed after enrolling 2,335 participants with obesity or overweight. No outcome data has been posted to the registry yet, and retatrutide remains an investigational drug with no marketing approval anywhere.
Once-Monthly Semaglutide Depot Begins Phase 1/2a Human Trial
A registry entry posted this week describes a Phase 1/2a study of a once-monthly semaglutide depot in adults with type 2 diabetes. If the formulation holds up in later trials, it would change the interval that millions of people currently build their GLP-1 protocols around.
GLP-1 Gastroparesis Reviewed as Aspiration Questions Persist
Two new publications tackle the same underlying problem from different ends: a PLOS One systematic review of GLP-1 gastroparesis cases, and an Anaesthesia letter on gastric contents and aspiration risk after semaglutide cessation. Both matter to anyone on an incretin drug who has a procedure coming up.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Retatrutide Grey Market Tested: Australian Study Checks Labels
A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.
Compounded Glutathione Recall Over Elevated Endotoxin Levels
An Austin, Texas compounding pharmacy has pulled specified lots of an injectable antioxidant preparation after its own testing flagged a contaminant that sterility testing does not catch. The compounded glutathione recall reaches the patient level, which means vials already dispensed to individuals are covered.